Man Group PLC Bei Gene, Ltd. Transaction History

Man Group PLC

$35.6 Billion
Q4 2024

A detailed history of Man Group PLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Man Group PLC holds 9,592 shares of BGNE stock, worth $2.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,592

Previous 76,227 87.42%

Holding current value

$2.17 Million

Previous $17.1 Million 89.65%

% of portfolio

0.0%

Previous 0.05%

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$174.72 - $246.04 $11.6 Million - $16.4 Million	-66,635 Reduced 87.42%	9,592 $1.77 Million
Q3 2024 Nov 14, 2024	BUY	$143.93 - $224.51 $9.65 Million - $15.1 Million	67,050 Added 730.63%	76,227 $17.1 Million
Q2 2024 Aug 14, 2024	BUY	$129.52 - $174.32 $303,335 - $408,257	2,342 Added 34.26%	9,177 $1.31 Million
Q1 2024 May 15, 2024	SELL	$141.8 - $181.47 $4.86 Million - $6.23 Million	-34,308 Reduced 83.39%	6,835 $1.07 Million
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $6.53 Million - $8.29 Million	41,143 New	41,143 $7.42 Million

Others Institutions Holding BGNE

# of Institutions

254

Shares Held

42.4M

Call Options Held

135K

Put Options Held

111K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account